Development and validation of sensitive LC/MS/MS method for quantitative bioanalysis of levonorgestrel in rat plasma and application to pharmacokinetics study

Ananthula, Suryatheja; Janagam, Dileep R.; Jamalapuram, Seshulatha; Johnson, James R.; Mandrell, Timothy D.; Lowe, Timothy J.

doi:10.1016/j.jchromb.2015.09.006

Cited by 16 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma LNG levels were analyzed according to the validated method developed in our laboratory . The method used liquid–liquid extraction and subsequent ultra high performance liquid chromatography (UHPLC)–tandem mass spectroscopy (MS/MS) analysis.…”

Section: Methodsmentioning

confidence: 99%

Injectable In Situ Forming Depot Systems for Long‐Acting Contraception

et al. 2017

Self Cite

View full text Add to dashboard Cite

Up to date, no long‐acting reversible contraceptive (LARC) is developed to be injectable through needles smaller than 18 G and can also provide contraception for more than 3 months after single injection. In this study, injectable polymeric in situ forming depot (ISD) systems are developed to have injectability through 21–23 G needles, and capability of sustained release of levonorgestrel (LNG) for at least 7 months in vitro and in vivo after single subcutaneous injection in rats. The systems are polymeric solutions composed of biodegradable poly(lactide‐co‐glycolide) and poly(lactic acid) polymers dissolved in a mixture of solvents like N‐methyl‐2‐pyrrolidone and benzyl benzoate or triethyl citrate. LNG released from ISD systems successfully suppressed the estrous cycle of rats at plasma concentration above 0.35 ng mL−1. At the end of the treatment, when LNG plasma concentration drops down to be nondetectable, predictable return of fertility is observed in rats. The designed ISD systems have great potential to be further developed into robust injectable LARCs that can be injected through a 21 G or smaller needle and achieve a variety of contraception durations with high patient compliance and low cost.

show abstract

Section: Methodsmentioning

confidence: 99%

Injectable In Situ Forming Depot Systems for Long‐Acting Contraception

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…As sustained release dosage forms are promising in other fields, the same were being developed in ocular diseases [27,28]. Subconjunctival erodible sustained release implant (Durasert ™ ) is being developed by psivida corp which is under safety and efficacy testing (phase I/II clinical trial) in patients with elevated intraocular pressure [29].…”

Section: Sustained Release Drug Deliverymentioning

confidence: 99%

Emerging Trends in Ocular Drug Delivery: A Review on Recent Updates

Imtiazul¹,

Auniq²

2017

J Neoplasm

View full text Add to dashboard Cite

The distance from cornea to retina (1.7 cm) appears to be the difficult path for most of the small molecule therapeutics. Ocular drug delivery is extreme difficult task owing to complexity and intricate barriers of the eye. However, there is an urgency and need to overcome these barriers for the treatment of sight threatening ocular complications. Delivery of drugs through topical application is compromised by physiological, static, dynamic and metabolic barriers. Currently, intravitreal therapy is a gold standard for targeting therapeutic entities to the posterior segment of the eye. Various viable platforms using topical non-invasive to invasive techniques are currently under development and may progress into efficient delivery platforms. In this review, recent advances/developments in ocular delivery were discussed.

show abstract

“…They have been shown significant efficiency in cancer and also in other forms of diseases [20][21][22][23][24][25]. Formulation type can alter their biological activity in favor of cancer treatment [26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%